WORK Medical Technology Group LTD financial statements
Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data WORK Medical Technology Group LTD files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2024
FY2024
FY2025
Revenue
19.7
13.6
11.5
9.85
Gross profit
4.42
4.14
2.87
2.34
Research and development
0.18
0.3
0.3
0.44
General and administrative
2.56
1.86
4.56
2.33
Operating expenses
3.78
3.73
6.91
4.84
Interest expense
0.35
0.39
0.56
0.5
Interest income
0
0.03
0.01
0.18
Other non-operating income
0.48
-0.3
0.38
1.41
Pre-tax income
1.11
0.11
-3.67
-1.08
Income tax
0.17
0.05
-0.13
0.12
Net income to minority interests
0.08
-0.05
-0.05
-0.13
Net income
0.87
0.11
-3.49
-1.07
EPS, basic
0.07
0.01
-0.27
-0.04
EPS, diluted
0.07
0.01
-0.27
-0.04
Shares, basic (weighted)
12.5
12.5
12.7
29
Shares, diluted (weighted)
12.5
12.5
12.7
29
Balance sheet
FY2022
FY2024
FY2024
FY2025
Cash and equivalents
0.73
1.6
6.56
4.09
Receivables
3.33
1.65
0.62
Inventory
4.62
3.18
2.46
Other current assets
4.86
1.63
1.28
Total current assets
22.2
20.8
20.5
Property, plant and equipment
6.63
11.4
10.6
Lease right-of-use assets
0.11
0.03
Intangible assets
1
1.04
0.96
Total assets
30
36.3
33.2
Accounts payable
3.96
1.5
1.72
Accrued liabilities
0.63
0.23
0.51
Deferred revenue
0.36
0.78
0.63
0.4
Short-term debt
8.84
13.3
6.39
Total current liabilities
18.9
20.2
12
Lease liabilities
0.05
0.02
Total liabilities
19
20.2
12
Paid-in capital
0.09
6.62
13
Retained earnings
9.58
6.08
4.96
Other comprehensive income
-0.68
-0.41
-0.61
Shareholders' equity
9.88
13.2
18.3
Minority interests
1.11
2.88
2.83
Total equity
11.2
11
16.1
21.2
Total liabilities and equity
30
36.3
33.2
Shares outstanding
12.5
14.6
Cash flow statement
FY2022
FY2024
FY2024
FY2025
Net income
0.94
0.06
-3.54
-1.2
Depreciation and amortization
3.26
1.6
1.41
0.92
Deferred income tax
-0.31
-0.09
-0.05
0.11
Change in receivables
-4.23
-0.13
1.82
1.02
Change in inventory
2.05
-0.4
1.58
0.57
Change in payables
-5.82
0.86
-2.55
0.25
Cash from operations
-2.26
2.21
-2.23
6.24
Capital expenditures
-2.01
-0.46
-9.23
-1.33
Cash from investing
-1.35
-0.58
-9.06
-7.61
Debt issued
9.11
13.4
18
Cash from financing
3.57
-0.73
15.7
-0.9
Exchange rate effect
-0.06
-0.03
0.56
-0.21
Net change in cash
-0.1
0.86
4.92
-2.47
Free cash flow
-4.27
1.75
-11.5
4.91
Interest paid
0.31
0.31
0.54
0.51
Income taxes paid
0.34
0.16
0.01
0.01
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.91 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
23.8%
Gross profit / revenue.
Pre-tax margin
-11.0%
Pre-tax income / revenue.
Net margin
-10.9%
Net income / revenue.
FCF margin
49.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
63.4%
Cash from operations / revenue.
Return on equity (ROE)
-6.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-3.1%
Net income / average total assets.
R&D / revenue
4.4%
Research and development expense / revenue.
Capex / revenue
13.5%
Capital expenditures / revenue.
D&A / revenue
9.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-14.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-20.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
-18.3%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-19.0%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
39.1%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-8.5%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
128.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
32.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.71x
Current assets / current liabilities.
Quick ratio
0.39x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.34x
(Cash + short-term investments) / current liabilities.
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.04
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.04
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.34
Revenue / diluted weighted shares.
FCF per share
$0.17
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.22
Cash from operations / diluted weighted shares.
Book value per share
$0.63
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.47x
Market cap / revenue.
P/B
0.25x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.27x
Market cap / tangible book value, when positive.
P/FCF
0.94x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
0.74x
Market cap / cash from operations, when positive.
EV/Sales
0.05x
Enterprise value / revenue.
EV/FCF
0.11x
Enterprise value / free cash flow, when both are positive.
FCF yield
106.4%
Free cash flow / market cap.
Earnings yield
-23.2%
Net income / market cap (the inverse of P/E).
What was WORK Medical Technology Group LTD's revenue in fiscal 2025?
WORK Medical Technology Group LTD reported revenue of $9.8M for fiscal 2025, 14.4% lower than the year before.
Was WORK Medical Technology Group LTD profitable in fiscal 2025?
No. It reported a net loss of $1.1M.
How much free cash flow did WORK Medical Technology Group LTD generate in fiscal 2025?
Cash from operations of $6.2M minus capital expenditures of $1.3M left free cash flow of $4.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.